Immunovant (IMVT) reported a fiscal Q4 net loss Thursday of $0.64 per diluted share, wider than a loss of $0.52 a year earlier.
Analysts polled by FactSet expected a loss of $0.69.
As of March 31, the company said it held about $714 million in cash and cash equivalents, which will finance its current programs through a key readout in Graves' disease anticipated in 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.